Health and Healthcare

Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

141 Articles

Chris Lange | Feb 25, 2019 at 12:25 PM EST

Which Gene Therapy Companies May Be Most Valuable After Spark Therapeutics Buyout

Spark Therapeutics shares more than doubled in Tuesday’s session as the result of its pending acquisition. However, the root of…

Jon C. Ogg | Dec 8, 2018 at 7:15 AM EST

Credit Suisse Issues Top Outperform Stock Picks for 2019

Many Wall Street firms are issuing their top picks and listing their favorite sectors and trends to consider for the…

Jon C. Ogg | Nov 3, 2018 at 7:30 AM EDT

8 Large Insider Buying Trades That Are Too Big to Ignore

After a big stock market sell-off and a subsequent snap-back rally, it’s always interesting to see how corporate directors…

Jon C. Ogg | Sep 6, 2018 at 9:00 AM EDT

Top Analyst Upgrades and Downgrades: Chevron, First Data, JD.com, MongoDB, PG&E, Rite Aid, Tilray, Vodafone and More

The top analyst upgrades, downgrades and initiations seen on Thursday include Chevron, First Data, JD.com, MongoDB, PG&E, Rite Aid, Tilray…

Trey Thoelcke | Aug 22, 2018 at 12:30 PM EDT

7 Biotech Stocks Insiders Are Loading Up On

La Jolla Pharmaceutical and Sarepta Therapeutics are among seven biotech stocks that have seen some notable insider trading recently.

Jon C. Ogg | Aug 1, 2018 at 9:10 AM EDT

Top Analyst Upgrades and Downgrades: Akamai, Apple, AutoZone, Dropbox, EA, Ford, Kinder Morgan, Pandora, P&G, Shopify and More

The include top analyst upgrades, downgrades and other research calls from Wednesday Akamai Technologies, Apple, AutoZone, Dropbox, Electronic Arts, Ford,…

Chris Lange | Jun 19, 2018 at 11:00 AM EDT

Why Sarepta Shares Are Skyrocketing

Sarepta Therapeutics shares skyrocketed on Tuesday after the firm presented positive preliminary results from its midstage Duchenne muscular dystrophy trial.

Lee Jackson | May 11, 2018 at 9:00 AM EDT

Top Analyst Upgrades and Downgrades: AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp, Sarepta Therapeutics and More

The top analyst upgrades, downgrades and other research calls from Friday included AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp…

Lee Jackson | Apr 18, 2018 at 8:20 AM EDT

4 Red-Hot Biotech Stocks to Buy Before Earnings

These four top Suntrust biotech picks for 2018 all have the potential for big upside moves if they do indeed…

Jon C. Ogg | Mar 13, 2018 at 9:10 AM EDT

Top Analyst Upgrades and Downgrades: AMD, Altice, Century Aluminum, Cerner, Chipotle, Cigna, GE, Micron, Noble Energy and More

The top analyst upgrades, downgrades and other research calls from Tuesday include AMD, Altice, Century Aluminum, Cerner, Chipotle, Cigna, GE,…

Jon C. Ogg | Mar 2, 2018 at 9:00 AM EST

Top Analyst Upgrades and Downgrades: BioMarin, CSX, Kinder Morgan, Microsemi, Splunk, US Steel, Walmart and More

The top analyst upgrades, downgrades and other research calls from Friday include BioMarin, CSX, Kinder Morgan, Microsemi, Splunk, U.S. Steel…

Jon C. Ogg | Dec 27, 2017 at 9:00 AM EST

Top Analyst Upgrades & Downgrades: Callaway, Capital One, Sarepta, Tesla, UnitedHealth, Wayfair and More

The top analyst upgrades, downgrades and other research calls from Wednesday include Callaway Golf, Capital One, Sarepta Therapeutics, Tesla, UnitedHealth…

Lee Jackson | Dec 21, 2017 at 8:25 AM EST

RBC Out With Top Pick Biotech Stocks to Buy for 2018

A new RBC report is reasonably positive on the biotech sector for the coming year. These eight top picks for…

Chris Lange | Nov 3, 2017 at 11:10 AM EDT

Sarepta Takes Another Big Step Forward With DMD Treatment

Sarepta Therapeutics saw its shares hit a new multiyear high on Friday after the firm announced that it received a…

Chris Lange | Oct 4, 2017 at 10:56 AM EDT

Amicus Therapeutics Wins Big at World Muscle Society Conference

Amicus Therapeutics is another biotech player seeing a nice boost from the World Muscle Society Conference in France.

1 2 3 4 5 6 … 10

Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

Which Gene Therapy Companies May Be Most Valuable After Spark Therapeutics Buyout

Credit Suisse Issues Top Outperform Stock Picks for 2019

8 Large Insider Buying Trades That Are Too Big to Ignore

Top Analyst Upgrades and Downgrades: Chevron, First Data, JD.com, MongoDB, PG&E, Rite Aid, Tilray, Vodafone and More

7 Biotech Stocks Insiders Are Loading Up On

Top Analyst Upgrades and Downgrades: Akamai, Apple, AutoZone, Dropbox, EA, Ford, Kinder Morgan, Pandora, P&G, Shopify and More

Why Sarepta Shares Are Skyrocketing

Top Analyst Upgrades and Downgrades: AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp, Sarepta Therapeutics and More

4 Red-Hot Biotech Stocks to Buy Before Earnings

Top Analyst Upgrades and Downgrades: AMD, Altice, Century Aluminum, Cerner, Chipotle, Cigna, GE, Micron, Noble Energy and More

Top Analyst Upgrades and Downgrades: BioMarin, CSX, Kinder Morgan, Microsemi, Splunk, US Steel, Walmart and More

Top Analyst Upgrades & Downgrades: Callaway, Capital One, Sarepta, Tesla, UnitedHealth, Wayfair and More

RBC Out With Top Pick Biotech Stocks to Buy for 2018

Sarepta Takes Another Big Step Forward With DMD Treatment

Amicus Therapeutics Wins Big at World Muscle Society Conference

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

NVIDIA’s New Quantum‑AI Models Are Impressive — and the Market Doesn’t Seem Ready to Price the Step‑Change

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

Which Gene Therapy Companies May Be Most Valuable After Spark Therapeutics Buyout

Credit Suisse Issues Top Outperform Stock Picks for 2019

8 Large Insider Buying Trades That Are Too Big to Ignore

Top Analyst Upgrades and Downgrades: Chevron, First Data, JD.com, MongoDB, PG&E, Rite Aid, Tilray, Vodafone and More

7 Biotech Stocks Insiders Are Loading Up On

Top Analyst Upgrades and Downgrades: Akamai, Apple, AutoZone, Dropbox, EA, Ford, Kinder Morgan, Pandora, P&G, Shopify and More

Why Sarepta Shares Are Skyrocketing

Top Analyst Upgrades and Downgrades: AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp, Sarepta Therapeutics and More

4 Red-Hot Biotech Stocks to Buy Before Earnings

Top Analyst Upgrades and Downgrades: AMD, Altice, Century Aluminum, Cerner, Chipotle, Cigna, GE, Micron, Noble Energy and More

Top Analyst Upgrades and Downgrades: BioMarin, CSX, Kinder Morgan, Microsemi, Splunk, US Steel, Walmart and More

Top Analyst Upgrades & Downgrades: Callaway, Capital One, Sarepta, Tesla, UnitedHealth, Wayfair and More

RBC Out With Top Pick Biotech Stocks to Buy for 2018

Sarepta Takes Another Big Step Forward With DMD Treatment

Amicus Therapeutics Wins Big at World Muscle Society Conference

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

NVIDIA’s New Quantum‑AI Models Are Impressive — and the Market Doesn’t Seem Ready to Price the Step‑Change

Featured Reads

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not